NCT00089245 - Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Biotech Hunter

Enrollment

177

Participants

Timeline

Start Date

February 5, 2004

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions

Brain and Central Nervous System TumorsNeuroblastomaSarcoma

Interventions

DRUG

Iodine I 131 MOAB 8H9

Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.

DRUG

Iodine I 131 MOAB 8H9

The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York